CELLECTISAct. Nom. News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.11.15	Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Product Candidates during the Upcoming ASH Annual Meeting (Businesswire)
05.11.15	Cellectis: UCART19: First in Man Proof of Concept to Be Presented at 2015 ASH Annual Meeting (Businesswire)
28.10.15	Successful GMP Production Process for UCART19 (Businesswire)
09.09.15	Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
08.09.15	Cellectis Reports Second Quarter and First Half Year 2015 Financial Results (Businesswire)
03.09.15	MD Anderson Cancer Center and Cellectis Announce a Broad Preclinical and Clinical Strategic Alliance in Cancer Immunotherapy (Businesswire)
26.08.15	Cellectis to Present Data on its CAR T-Cell Immunotherapy Programs During Upcoming Conferences (Businesswire)
16.07.15	Cellectis Announces Publication of an Article in Cancer Research on Allogeneic CAR T-cell Immunotherapies (Businesswire)
08.07.15	Cellectis Reaches Milestone in Servier Collaboration (Businesswire)
10.06.15	Cellectis Announces Promising Study on Next Generation Engineered Allogeneic CAR T-cells (Businesswire)
09.06.15	S&W Seed Company and Calyxt, Inc. Announce Alfalfa Seed Collaboration (Businesswire)
09.06.15	Cellectis Reports First Quarter 2015 Financial Results (Businesswire)
05.06.15	Cellectis to Present Data on its Allogeneic CAR T-Cell Immunotherapy Programs at the European Hematology Association Annual Meeting (Businesswire)
02.06.15	Weill Cornell Medical College and Cellectis Announce Research Alliance Advancing Drug Discovery and the Translation of Novel Immunotherapies in Leukemia (Businesswire)
20.05.15	Cellectis SA Combined General Shareholders’ Meeting of May 18, 2015 (Businesswire)
08.05.15	Cellectis S.A. to Present Data on its Allogeneic CAR T Cell Programs at American Society of Gene & Cell Therapy Annual Meeting (Businesswire)
05.05.15	Cellectis S.A. Announces Calyxt is New Name for Its Plant Sciences Subsidiary (Businesswire)
16.04.15	Cellectis Plant Sciences, Inc. Locks Early CRISPR Intellectual Property Uses in Plants (Businesswire)
15.04.15	Cellectis Plant Sciences, Inc. Publishes a Study Demonstrating Reduced Acrylamide in Fried Potatoes (Businesswire)
10.04.15	Cellectis Announces Presentations at Upcoming Conferences (Businesswire)
09.04.15	Cellectis Opens Labs and Offices in Manhattan, New York (Businesswire)
25.03.15	Cellectis Prices Initial Public Offering of American Depositary Shares (Businesswire)
04.03.15	Cellectis: 2014 Financial Results (Businesswire)
17.02.15	Cellectis SA Shareholders General Meeting of February 16, 2015 (Businesswire)
13.01.15	Cellectis and Ohio State University, Through the Ohio State Innovation Foundation, Enter Into Licensing Agreement for Chimeric Antigen Receptor Technology Targeting Multiple Myeloma (Businesswire)
08.01.15	Cellectis Plans to Conduct Registered Initial Public Offering in the U.S. (Businesswire)
06.01.15	Cellectis Announces the Issuance by the USPTO of a Patent Covering a Seminal Nuclease-Based "gene editing” Method (Businesswire)
18.12.14	Cellectis Plant Sciences and Two Blades Foundation Announce the Execution of a Cross-License Agreement on TAL Effector Nuclease Technologies (Businesswire)
24.11.14	Cellectis Announces Upcoming Presentations at the 56th Annual Meeting of the American Society of Hematology (ASH) (Businesswire)
12.11.14	Cellectis Received Proceeds of €13 Million Through the Exercise of Warrants (Businesswire)
04.11.14	Cellectis: TALENTM Technology: Grant of EP 2 510 096 by the European Patent Office (Businesswire)
30.10.14	Cellectis: Event Report: Individual Shareholders’ Meeting Held on October 23, 2014 (Businesswire)
30.09.14	Cellectis: First-Half 2014 Financial Results (Businesswire)
29.09.14	Cellectis Plant Sciences Launches Its New Website (Businesswire)
23.09.14	Cellectis : Individual Shareholder Meeting (Businesswire)
16.09.14	Event report: Cellectis R&D/ Analyst Day (Businesswire)
04.09.14	Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc. (Businesswire)
02.09.14	Cellectis: Genome Engineering & CART Cells: At the Forefront of Immuno-Oncology (Businesswire)
31.07.14	Pfizer’s Stake in Cellectis’ Capital is Welcomed by Its Shareholders (Businesswire)
29.07.14	Cellectis Sells Its Swedish Subsidiary, Cellectis AB, to the Japanese Company Takara Bio Inc. (Businesswire)
30.06.14	Cellectis SA Combined General Shareholders’ Meeting of June 27, 2014 (Businesswire)
25.06.14	Cellectis R&D / Analyst Day (Businesswire)
23.06.14	Cellectis’ UCART19 Receives Advanced-Therapy Medicinal Product Classification from EMA (Businesswire)
19.06.14	Cellectis To Participate in the Piper Jaffray GenomeRx Symposium on June 23, 2014 (Businesswire)
18.06.14	Pfizer and Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration (Businesswire)
10.06.14	Cellectis to Present New Data Update on Its Allogeneic CAR T Cell Therapeutics at the 19th Congress of the European Hematology Association (EHA) (Businesswire)
09.06.14	Cellectis enters into an agreement with CELLforCURE for the cGMP manufacturing of allogeneic CART cells (Businesswire)
05.06.14	Cellectis and Accelera (Nerviano Medical Sciences Group) Sign an Agreement to Complete Preclinical Studies of Cellectis’ Lead Product Candidate UCART19 (Businesswire)
05.06.14	Cellectis and Thermo Fisher Scientific Enter Into Agreements on TALEN™, a Leading Gene Editing Technology (Businesswire)
29.05.14	Cellectis plant sciences reports improvement of oil content in algae (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu CELLECTISAct. Nom.

Aktien Top/Flop

Meistgelesene Nachrichten